Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/58083
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Brito, Pedro | por |
dc.contributor.author | Costa, Jorge | por |
dc.contributor.author | Gomes, Nuno | por |
dc.contributor.author | Costa, Sandra | por |
dc.contributor.author | Correia-Pinto, Jorge | por |
dc.contributor.author | Silva, Rufino | por |
dc.date.accessioned | 2019-01-11T15:25:06Z | - |
dc.date.available | 2019-01-11T15:25:06Z | - |
dc.date.issued | 2018-07 | - |
dc.identifier.citation | Brito, P., Costa, J., Gomes, N., Costa, S., Correia-Pinto, J., & Silva, R. (2018). Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF. Journal of diabetes and its complications | por |
dc.identifier.issn | 1056-8727 | - |
dc.identifier.issn | 1873-460X | - |
dc.identifier.uri | https://hdl.handle.net/1822/58083 | - |
dc.description | Accepted manuscript | por |
dc.description.abstract | To study the relationship between systemic pro-inflammatory factors and macular structural response to intravitreal bevacizumab for diabetic macular edema (DME). | por |
dc.description.abstract | Purpose To study the relationship between systemic pro-inflammatory factors and macular structural response to intravitreal bevacizumab for diabetic macular edema (DME). Methods Prospective study including 30 cases with DME, treated with bevacizumab and a minimum follow-up of 6 months. All cases underwent baseline laboratory testing for cardiovascular risk (high sensitivity C-reactive protein (hsCRP), homocystein), dyslipidemia, renal dysfunction and glucose control. Serum levels of VEGF, soluble ICAM-1, MCP-1 and TNF-α were assessed by enzyme-linked immunosorbent assay kits. Significant associations between systemic factors and quantitative and qualitative spectral-domain optical coherence macular features were analyzed. Results A mean of 4.82 ± 0.56 intravitreal injections was performed, resulting in significant improvement of central foveal thickness (CFT) (p < 0.001). A significant association with third month CFT decrease <10% was found for hsCRP (3.33 ± 2.01 vs 1.39 ± 1.15 mg/l, p = 0.007) and ICAM1 (975.54 ± 265.49 vs 727.07 ± 336.09 pg/ml, p = 0.012). ROC curve analysis indicated hsCRP and ICAM1 as significant biomarkers for 3rd month reduced anatomic response (area under the curve (AUC) = 0.807, p = 0.009 for hsCRP; AUC = 0.788, p = 0.014 for ICAM1). ROC curve analysis revealed hsCRP as a significant biomarker for 6th month CFT decrease <10% (AUC = 0.903, p < 0.001, cutoff value = 1.81 mg/l). A significant association with 6th month CFT decrease ≥25% was found for serum MCP1 (244.69 ± 49.34 pg/ml vs 319.24 ± 94.88 pg/ml, p = 0.017) and serum VEGF (90.84 ± 37.33 vs 58.28 ± 25.19 pg/ml, p = 0.027). The combined model of serum VEGF and LDL-cholesterol was found to be predictive of 6th month hard exudate severity (p = 0.001, r2 = 0.463). Conclusions Increased levels of hsCRP and ICAM1 were found to be significant biomarkers for early reduced anatomic response to anti-VEGF treatment. Cases with higher serum levels of such factors had increased CFT values, despite treatment, suggesting inner blood-retinal barrier breakdown that is not adequately responsive to anti-VEGF monotherapy | por |
dc.description.sponsorship | Portuguese Society of Ophthalmology | por |
dc.language.iso | eng | por |
dc.publisher | Elsevier Science Inc | por |
dc.rights | openAccess | por |
dc.subject | Anti-VEGF | por |
dc.subject | Bevacizumab | por |
dc.subject | C-reactive protein | por |
dc.subject | Diabetic macular edema | por |
dc.subject | Inflammatory biomarkers | por |
dc.title | Serological inflammatory factors as biomarkers for anatomic response in diabetic macular edema treated with anti-VEGF | por |
dc.type | article | por |
dc.peerreviewed | yes | por |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S105687271830148X | por |
oaire.citationStartPage | 643 | por |
oaire.citationEndPage | 649 | por |
oaire.citationIssue | 7 | por |
oaire.citationVolume | 32 | por |
dc.identifier.doi | 10.1016/j.jdiacomp.2018.05.006 | por |
dc.subject.fos | Ciências Médicas::Medicina Básica | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | por |
dc.subject.wos | Science & Technology | por |
sdum.journal | Journal of Diabetes and Its Complications | por |
Aparece nas coleções: | ICVS - Artigos em revistas internacionais / Papers in international journals |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
brito2018 vct.pdf | 2,19 MB | Adobe PDF | Ver/Abrir |